Gundogdu et al. (2025) develop and validate an ICP-MS method for the determination of aluminum (Al), sodium (Na), and potassium (K) in human albumin infusion solutions, a pharmaceutical parenteral nutrition product. The method is validated according to pharmaceutical analytical method validation guidelines. The clinical motivation is that aluminum contamination of albumin infusion solutions poses a toxicity risk, particularly in neonates and premature infants receiving parenteral nutrition.
Key numbers
Al LOD: 2.06 × 10^-4 µg/mL (0.000206 µg/mL = 0.206 µg/L = 0.206 ppb) in albumin infusion solutions. This exceptionally low LOD reflects the ICP-MS capability and the dilution-based sample preparation. The FDA limit for Al in large-volume parenteral (LVP) solutions is 25 µg/L; this method has ample headroom to detect contamination well below that threshold.
Methods (brief)
ICP-MS with sample preparation by dilution or microwave acid digestion. Pharmaceutical albumin infusion matrix — not a food matrix, but highly relevant to the neonatal Al exposure issue (premature infants receiving parenteral nutrition are a recognized high-risk group for Al toxicity from parenteral sources). CC BY license. Method validated per ICH or USP guidelines.
Implications
Certification: Not a direct HMT&C food product certification target, but the clinical context is important: neonates on parenteral nutrition receive significant Al from albumin infusions, a parallel exposure route to dietary Al from infant formula. The wiki’s health/aluminum-infant page should reference this pharmaceutical-route exposure alongside dietary exposure.
Courses: Illustrates the distinction between dietary Al exposure (food route) and parenteral Al exposure (intravenous route), both of which matter for total Al burden in the most vulnerable neonates.